Table 3.

Correlations between serum GM3 (d18:1-16:0, d18:1-24:1) levels and clinical parameters in patients with lymphoid neoplasms.

Characteristic	Patients (n)	Serum GM3 (d18:1-16:0) ng/μL	P	Serum GM3 (d18:1-24:1) ng/μL	P
Age
<60 years	5	1.62 ± 0.440	0.85	1.25 ± 0.362	1.00
≥60 years	21	1.66 ± 0.678		1.30 ± 0.566
Disease status
At diagnosis	20	1.62 ± 0.653	0.53	1.17 ± 0.355	<0.05
At relapse or in regression	6	1.76 ± 0.594		1.69 ± 0.809
Bone marrow involvement
Absence	11	1.36 ± 0.346	0.06	1.16 ± 0.224	0.36
Presence	15	1.87 ± 0.713		1.38 ± 0.660
Extranodal involvement
Absence	6	1.33 ± 0.252	0.27	1.19 ± 0.183	0.93
Presence	20	1.75 ± 0.683		1.32 ± 0.594
B symptoms
Absence	21	1.64 ± 0.650	1.00	1.29 ± 0.547	0.75
Presence	5	1.69 ± 0.615		1.29 ± 0.488
Clinical classification
Low grade lymphoma	15	1.72 ± 0.752	0.838	1.30 ± 0.63	0.721
High grade lymphoma	11	1.55 ± 0.433		1.27 ± 0.37
Ann Arbor stage
I–III	6	1.34 ± 0.286	0.27	1.22 ± 0.238	1.00
IV	20	1.74 ± 0.681		1.31 ± 0.590
Index for lymphoma †
IPI
1–3	14	1.57 ± 0.569	0.88	1.39 ± 0.663	0.32
4, 5	3	1.52 ± 0.360		1.28 ± 0.0798
aaIPI
Low, Low-intermediate risk	10	1.26 ± 0.274	<0.01	1.12 ± 0.248	<0.05
High-intermediate, High risk	7	2.00 ± 0.511		1.72 ± 0.788
Index for CLL
Rai stage
0–1	3	1.20 ± 0.435	0.11	0.850 ± 0.319	0.11
2–4	4	2.48 ± 0.694		1.31 ± 0.273

Statistical significance was determined using the Mann-Whitney U test.

Low grade lymphoma includes CLL, LPL, plasma cell myeloma, follicular lymphoma, mantle cell lymphoma; high grade lymphoma includes DLBCL, PTCL.

^†Lymphoma consists of lymphoid neoplasms excluding CLL and plasma cell myeloma.

IPI, International Prognostic Index; aaIPI, Age-Adjusted International Prognostic Index.